ECSP055859A - Forma cristalina alfa del renelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen - Google Patents
Forma cristalina alfa del renelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienenInfo
- Publication number
- ECSP055859A ECSP055859A EC2005005859A ECSP055859A ECSP055859A EC SP055859 A ECSP055859 A EC SP055859A EC 2005005859 A EC2005005859 A EC 2005005859A EC SP055859 A ECSP055859 A EC SP055859A EC SP055859 A ECSP055859 A EC SP055859A
- Authority
- EC
- Ecuador
- Prior art keywords
- crystalline form
- strontium
- renelato
- alfa
- procedure
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Steroid Compounds (AREA)
Abstract
La forma alfa cristalina de ranelato de estroncio de la fórmula (I): caracterizada por su diagrama de poder de difracción de Rayos X, y por un contenido de agua de 22 a 24%.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0410335A FR2875807B1 (fr) | 2004-09-30 | 2004-09-30 | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055859A true ECSP055859A (es) | 2006-09-18 |
Family
ID=34942420
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005859A ECSP055859A (es) | 2004-09-30 | 2005-06-16 | Forma cristalina alfa del renelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen |
Country Status (42)
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
US20070292535A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating arthritic and or osteoporitic conditions |
US20070292529A1 (en) * | 2006-06-19 | 2007-12-20 | Tabbiner Philip S | Strontium compositions and methods of treating osteoporotic conditions |
CN101206208B (zh) * | 2006-12-19 | 2011-08-10 | 北京德众万全药物技术开发有限公司 | 一种用hplc法分析雷尼酸锶原料及其制剂的方法 |
KR20110066197A (ko) | 2008-09-29 | 2011-06-16 | 라티오팜 게엠베하 | 스트론튬 라넬레이트의 무수물 및 수화물 형태 |
IT1398542B1 (it) * | 2010-03-05 | 2013-03-01 | Chemelectiva S R L | Processo per la preparazione di un polimorfo |
CN102241663B (zh) * | 2010-05-10 | 2013-02-13 | 山东方明药业集团股份有限公司 | 一种雷奈酸锶八水合物的制备方法 |
WO2012143932A1 (en) * | 2011-04-21 | 2012-10-26 | Shilpa Medicare Limited | Crystalline strontium ranelate form-s |
CZ2011320A3 (cs) | 2011-05-30 | 2012-12-12 | Zentiva, K.S. | Stabilní krystalická forma X stroncium ranelátu |
EP2530068A1 (en) | 2011-05-31 | 2012-12-05 | Lacer, S.A. | New strontium salts, synthesis and use thereof in the treatment of osteoporosis |
WO2013013003A1 (en) | 2011-07-21 | 2013-01-24 | Emory University | Methods for treating inflamatory conditions and states, and cancers by antagonizing nf-kb activation |
CN102503931A (zh) * | 2011-09-20 | 2012-06-20 | 浙江华海药业股份有限公司 | 一种雷尼酸锶晶形h的制备方法 |
WO2013113319A1 (en) * | 2012-01-31 | 2013-08-08 | Pharmathen S.A. | Process for the preparation of strontium ranelate, intermediate or hydrates thereof |
EP2641905A1 (en) | 2012-03-23 | 2013-09-25 | Urquima S.A. | Solid forms of strontium ranelate and processes for their preparation |
US8569514B1 (en) | 2012-05-17 | 2013-10-29 | Divi's Laboratories, Ltd. | Process for the preparation of strontium ranelate |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2651497B1 (fr) * | 1989-09-01 | 1991-10-25 | Adir | Nouveaux sels de metaux bivalents de l'acide n, n-di (carboxymethyl)amino-2 cyano-3 carboxymethyl-4 carboxy-5 thiophene, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
NZ272608A (en) | 1994-07-22 | 2000-05-26 | Lilly Co Eli | Inhibiting bone loss by administering a bisphosphonate and a second compound selected from various compounds, including 2-phenyl-3-aroylbenzothienes; bisphosphonate combination salts |
FR2749759B1 (fr) * | 1996-06-17 | 1999-11-26 | Adir | Utilisation de sels de strontium pour l'obtention de compositions pharmaceutiques destinees au traitement de l'arthrose |
DE19642451A1 (de) | 1996-10-15 | 1998-04-16 | Merck Patent Gmbh | Aminothiophencarbonsäureamide |
WO2003028665A2 (en) * | 2001-10-03 | 2003-04-10 | Teva Pharmaceutical Industries Ltd. | Methods for the purification of levofloxacin |
ES2412306T3 (es) * | 2002-01-09 | 2013-07-11 | Emisphere Technologies, Inc. | Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio |
US7396839B2 (en) * | 2002-08-06 | 2008-07-08 | Teva Pharmaceuticals Usa, Inc. | Crystalline forms of gatifloxacin |
FR2844795B1 (fr) * | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel du ranelate de strontium et de ses hydrates |
FR2844797B1 (fr) | 2002-09-24 | 2004-10-22 | Servier Lab | Nouveau procede de synthese industriel des tetraesters de l'acide 5-[bis (carboxymethyl)]-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
FR2844796A1 (fr) | 2002-09-24 | 2004-03-26 | Servier Lab | Nouveau procede de synthese industrielle du diester methylique de l'acide 5-amino-3-carboxymethyl-4-cyano-2- thiophenecarboxylique, et application a la synthese des sels bivalents de l'acide ranelique et de leurs hydrates |
FR2875807B1 (fr) * | 2004-09-30 | 2006-11-17 | Servier Lab | Forme cristalline alpha du ranelate de strontium, son procede de preparation, et les compositions pharmaceutiques qui la contiennent |
-
2004
- 2004-09-30 FR FR0410335A patent/FR2875807B1/fr not_active Expired - Fee Related
-
2005
- 2005-05-24 PE PE2005000574A patent/PE20060364A1/es not_active Application Discontinuation
- 2005-05-26 MA MA28300A patent/MA27815A1/fr unknown
- 2005-05-27 GT GT200500130A patent/GT200500130A/es unknown
- 2005-05-30 CA CA002508824A patent/CA2508824C/fr not_active Expired - Fee Related
- 2005-05-31 AP AP2005003323A patent/AP1930A/xx active
- 2005-05-31 US US11/140,822 patent/US7459568B2/en not_active Expired - Fee Related
- 2005-06-02 OA OA1200500169A patent/OA13013A/fr unknown
- 2005-06-14 AR ARP050102423A patent/AR049395A1/es not_active Application Discontinuation
- 2005-06-15 SA SA05260168A patent/SA05260168B1/ar unknown
- 2005-06-15 MX MXPA05006407A patent/MXPA05006407A/es active IP Right Grant
- 2005-06-15 CR CR7876A patent/CR7876A/es not_active Application Discontinuation
- 2005-06-16 CN CNB2005100753929A patent/CN100391956C/zh not_active Expired - Fee Related
- 2005-06-16 CO CO05058754A patent/CO5710195A1/es not_active Application Discontinuation
- 2005-06-16 IL IL169237A patent/IL169237A/en not_active IP Right Cessation
- 2005-06-16 EC EC2005005859A patent/ECSP055859A/es unknown
- 2005-06-17 PT PT05291297T patent/PT1642897E/pt unknown
- 2005-06-17 NZ NZ540802A patent/NZ540802A/en not_active IP Right Cessation
- 2005-06-17 TW TW094120331A patent/TWI367881B/zh not_active IP Right Cessation
- 2005-06-17 ZA ZA200504937A patent/ZA200504937B/en unknown
- 2005-06-17 AU AU2005202718A patent/AU2005202718B2/en not_active Ceased
- 2005-06-17 EP EP08007270A patent/EP1944302A1/fr not_active Withdrawn
- 2005-06-17 WO PCT/FR2005/001515 patent/WO2006035122A1/fr active Application Filing
- 2005-06-17 RS RSP-2008/0506A patent/RS51110B/sr unknown
- 2005-06-17 UA UAA200505970A patent/UA80008C2/uk unknown
- 2005-06-17 EA EA200500842A patent/EA008474B1/ru not_active IP Right Cessation
- 2005-06-17 AT AT05291297T patent/ATE411308T1/de active
- 2005-06-17 SI SI200530490T patent/SI1642897T1/sl unknown
- 2005-06-17 ES ES05291297T patent/ES2314593T3/es active Active
- 2005-06-17 SG SG200503938A patent/SG121035A1/en unknown
- 2005-06-17 BR BRPI0502228-2A patent/BRPI0502228A/pt not_active IP Right Cessation
- 2005-06-17 JP JP2005177199A patent/JP2006104184A/ja active Pending
- 2005-06-17 PL PL05291297T patent/PL1642897T3/pl unknown
- 2005-06-17 GE GEAP20058848A patent/GEP20074106B/en unknown
- 2005-06-17 DE DE602005010359T patent/DE602005010359D1/de active Active
- 2005-06-17 NO NO20052998A patent/NO333948B1/no not_active IP Right Cessation
- 2005-06-17 DK DK05291297T patent/DK1642897T3/da active
- 2005-06-17 EP EP05291297A patent/EP1642897B9/fr not_active Revoked
- 2005-07-01 PA PA20058638201A patent/PA8638201A1/es unknown
- 2005-07-08 KR KR1020050061542A patent/KR100816590B1/ko not_active IP Right Cessation
-
2006
- 2006-05-29 HK HK06106187A patent/HK1086260A1/xx not_active IP Right Cessation
-
2008
- 2008-08-12 US US12/228,381 patent/US7745482B2/en not_active Expired - Fee Related
- 2008-11-19 CY CY20081101327T patent/CY1108797T1/el unknown
- 2008-12-16 HR HR20080652T patent/HRP20080652T3/xx unknown
-
2010
- 2010-01-07 JP JP2010001847A patent/JP2010132669A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055859A (es) | Forma cristalina alfa del renelato de estroncio, procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
AR053147A1 (es) | Forma cristalina del clorhidrato de ivabradina, un procedimiento para su preparacion y composiciones farmaceuticas que la contienen | |
NI200800294A (es) | Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmacéuticas que la contienen. | |
BRPI0621386B8 (pt) | composição farmacêutica para o uso externo | |
GT200600086A (es) | Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen | |
CR8647A (es) | Forma cristalina delta-d de clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmacueticas que la contienen | |
EA200601271A1 (ru) | Новая кристаллическая форма iv агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
EA200601273A1 (ru) | Новая кристаллическая форма v агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
MY151295A (en) | Pyrimidyl indoline compound | |
ME01284B (me) | Organska jedinjenja | |
MEP8009A (en) | Pyrido (2, 3-d) pyrimidin0ne compounds and their use as pi3 inhibitors | |
RS51563B (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING ROOSUVASTATIN CALCIUM | |
EA200601274A1 (ru) | Новая кристаллическая форма iii агомелатина, способ её получения и фармацевтические композиции, которые её содержат | |
AR074507A1 (es) | Forma cristalina del clorhidrato de nalmefeno dihidratado, metodos para obtenerla, composiciones farmaceuticas que contienen dicha forma cristalina, uso de las mismas en el tratamiento del alcoholismo y un metodo de recuperacion de la forma cristalina anhidra. | |
ES2421512T3 (es) | Composiciones orales que contienen compuestos antibacterianos bifenólicos | |
RU2012140474A (ru) | Композиции для ухода за полостью рта | |
ATE540667T1 (de) | Verbindungen mit kühlender wirkung | |
SG178975A1 (en) | Indenone derivative and pharmaceutical composition comprising same | |
AR034120A1 (es) | Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico | |
NO20085317L (no) | Imidazoazepinonforbindelser | |
AR075418A1 (es) | Polimorfo cristalino de 3-{[5-(azetidin-1-ilcarbonil)pirazin-2-il]oxi}-5-{[(1s)-1-metil-2-(metiloxi)etil]oxi}-n-(5-metilpirazin-2-il)benzamida,composiciones farmaceuticas que los contienen, proceso para prepararla y uso de las mismas para el tratamiento de la diabetes tipo ii y/u obesidad. | |
BRPI0508232A (pt) | sìntese de epotilonas, intermediários das mesmas, análogos e usos das mesmas | |
AR057555A1 (es) | Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo | |
BRPI0407519A (pt) | derivados de benzofurano | |
WO2008126652A1 (ja) | 皮膚外用組成物 |